益髓补肾方改善恶性淋巴瘤化疗患者相关性贫血及对免疫功能的影响  

Effect of Yisui Bushen Formula in Improving Malignant Lymphoma Chemotherapy-related Anemia and Immune Function

作　　者：王永敏[1] 郑雪梅[2] 刘英 胡冬菊[1] 肖汇颖[1] 郭子敬[1] 

机构地区：[1]河北省中医院,石家庄050011 [2]哈励逊国际和平医院,河北衡水053000 [3]保定市徐水区中医医院,河北保定072550

出　　处：《中国实验方剂学杂志》2017年第19期180-185,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：河北省中医药管理局科研计划项目(2014030)

摘　　要：目的:探讨益髓补肾方改善恶性淋巴瘤化疗患者相关性贫血临床疗效,观察其对免疫功能的影响。方法:选取河北省中医院血液病科2010年1月—2015年12月收治的恶性淋巴瘤化疗相关性贫血患者110例,按随机数字表法分为对照组和治疗组,各55例,对照组常规化疗;治疗组在常规化疗基础上予以益髓补肾方(1剂/d)口服治疗,治疗15 d为1疗程,共治疗2个疗程。两组采血测定血常规,记录生活质量,同时比较临床疗效及并发症。结果:对照组总有效率为69.09%,治疗组有效率为89.09%,治疗组优于对照组(P<0.05);与治疗前比较,两组治疗后血红蛋白(Hb),血细胞比容(Hct),红细胞计数(RBC)含量升高(P<0.05),促红细胞生成素(EPO)含量降低(P<0.05);治疗后躯体、角色、社会、情绪等指标评分升高(P<0.05);治疗后与对照组比较,治疗组治疗后Hb,Hct,RBC含量较高,EPO含量降低,治疗后躯体、角色、社会、情绪等评分升高(P<0.05);治疗组T淋巴细胞亚群CD3^+,CD4^+,CD4^+/CD8^+水平升高,CD8^+细胞水平下降(P<0.05);对照组不良反应发生率为12.73%,治疗组不良反应发生率为7.27%,治疗组低于对照组(P<0.05)。结论:益髓补肾方治疗恶性淋巴瘤化疗相关性贫血疗效确切,可提高生活质量及患者免疫功能,具有较好的增效减毒作用。Objective： To investigate the clinical effect of Yisui Bushen formula in improving malignant lymphoma chemotherapy-related anemia and immune function. Method： Totally 110 cases of malignant lymphoma chemotherapy-related anemia patients treated in our Haematology Department from January 2010 to December 2015 were selected and randomly divided into treatment group and control group according to random number table method, with 55 cases in each group. The control group was given conventional chemotherapy, while the treatment group was given Yisui Bushen formula for oral treatment （1/d） in addition to conventional chemotherapy. One course of treatment was 15 days, and they received 2 courses of treatment. Blood routine examination was performed, and the quality of life, clinical curative effect and complications of the two groups were observed and compared. Result： The total effective rate of the control group was 69.09% , whereas the total effective rate of the treatment group was 89.09% , indicating a statistically significant difference （P 〈 0.05）. Compared with before treatment, hemoglobin （Hb）, hematocrit （Hct）, red blood cell （RBC） content of the two groups increased after treatment （ P 〈 0.05 ）, while the recombinant human erythropoietin （ EPO ） content reduced, suggesting statistically significant differences （P 〈 0.05）. After treatment, scores of body, role, social, emotional, and other indicators were increased, indicating statistically significant differences （P 〈 0.05）. The effectiveness of treatment group was 87.80% , which was higher than 68.29% of control group （P 〈 0.05）. After treatment, the levels of CD3^＋, CD4^＋, CD4^＋/CD8^＋ and CD8^＋ cells in treatment group were significantly lower than those in control group （P 〈0.05）. The incidence of adverse reactions of control group was 12.73% , whereas the incidence of adverse reactions of treatment group was 7.27% , indicating a statistically significant difference in adverse reactions

关 键 词：益髓补肾方 恶性淋巴瘤 化疗相关性贫血 生活质量 增效减毒 免疫功能 

分 类 号：R287[医药卫生—中药学] R259[医药卫生—中医学]